P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial

2021 ◽  
Vol 21 ◽  
pp. S139-S140
Author(s):  
Dieter Ayers ◽  
Shannon Cope ◽  
Devender S. Dhanda ◽  
Kevin Towle ◽  
Ali Mojebi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Expert Elicitation ◽  
Phase 2 ◽  
Term Survival ◽  
Long Term Survival ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Trial

scholarly journals Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Haematologica ◽  
2015 ◽  
Vol 100 (10) ◽  
pp. 1327-1333 ◽  
Author(s):  
M. A. Dimopoulos ◽  
K. C. Weisel ◽  
K. W. Song ◽  
M. Delforge ◽  
L. Karlin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Term Survival ◽  
Long Term Survival ◽  
Refractory Multiple Myeloma

Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances

2021 ◽  
pp. 1-6
Author(s):  
Lorena Bojalil-Alvarez ◽  
Morie A. Gertz ◽  
Elizabeth Garcia-Villaseñor ◽  
José Antonio Fernández-Gutiérrez ◽  
Oscar Alfonso Reyes-Cisneros ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Institution ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

2018 ◽  
Vol 180 (6) ◽  
pp. 821-830 ◽  
Author(s):  
Paul G. Richardson ◽  
William I. Bensinger ◽  
Carol Ann Huff ◽  
Caitlin L. Costello ◽  
Nikoletta Lendvai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Trial

Predicting Long-term Survival in Multiple Myeloma Patients Following Autotransplants

2003 ◽  
Vol 44 (5) ◽  
pp. 749-758 ◽  
Author(s):  
Athanasios B.-T. Fassas ◽  
Frits Van Rhee ◽  
Guido Tricot
Keyword(s):  
Multiple Myeloma ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

2014 ◽  
Vol 167 (4) ◽  
pp. 563-565 ◽  
Author(s):  
Craig B. Reeder ◽  
Donna E. Reece ◽  
Vishal Kukreti ◽  
Joseph R. Mikhael ◽  
Christine Chen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Induction Therapy ◽  
Newly Diagnosed ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document